Causal relationship between the gut microbiota, immune cells, and coronary heart disease: a mediated Mendelian randomization analysis
Open Access
- 5 August 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 15, 1449935
Abstract
Background: Recent studies have shown that the gut microbiota (GM), immune cells, and coronary heart disease (CHD) are closely related, but the causal nature of these relationships is largely unknown. This study aimed to investigate this causal relationship and reveal the effect of GM and immune cells on the risk of developing CHD using mediated Mendelian randomization (MR) analysis.Methods: First, we searched for data related to GM, immune cells, and CHD through published genome-wide association studies (GWAS). We filtered the single nucleotide polymorphisms (SNPs) associated with GM and immune cells and then performed the first MR analysis to identify disease-associated intestinal bacteria and disease-associated immune cells. Subsequently, three MR analyses were conducted: from disease-associated GM to disease-associated immune cells, from disease-associated immune cells to CHD, and from disease-associated GM to CHD. Each MR analysis was conducted using inverse variance weighting (IVW), MR-Egger regression, weighted median, weighted models, and simple models.Results: A total of six GM and 25 immune cells were found to be associated with CHD. In the MR analysis using the inverse variance weighting (IVW) method, g__Desulfovibrio.s__Desulfovibrio_piger was associated with EM DN (CD4–CD8–) %T cells (P < 0.05 and OR > 1), EM DN (CD4–CD8–) %T cells was associated with CHD (P < 0.05 and OR < 1), and g__Desulfovibrio.s__Desulfovibrio_piger was associated with CHD (P < 0.05 and OR < 1).Conclusion: An increase in the abundance of g__Desulfovibrio.s__Desulfovibrio_piger leads to an increase in the amount of EM DN (CD4–CD8–) %T cells, and an increase in the amount of EM DN (CD4–CD8–) %T cells reduces the risk of developing CHD. Our study provides some references for reducing the incidence of CHD by regulating GM and immune cells.Keywords
Funding Information
- Guangxi University of Chinese Medicine
This publication has 67 references indexed in Scilit:
- An In Vitro Evaluation of the Effect of Bifidobacterium longum L556 on Microbiota Composition and Metabolic Properties in Patients with Coronary Heart Disease (CHD)Probiotics and Antimicrobial Proteins, 2024
- Chinese Herbal Medicines for Coronary Heart Disease: Clinical Evidence, Pharmacological Mechanisms, and the Interaction with Gut MicrobiotaDrugs, 2024
- Mendelian Randomization as a Tool for Cardiovascular ResearchJAMA Cardiology, 2024
- TCRαβ+ CD4−/CD8– “double negative” T cells in health and disease—implications for the kidneyKidney International, 2022
- Dynamics of the normal gut microbiota: A longitudinal one-year population study in SwedenCell Host & Microbe, 2022
- Human gut microbiome impacts skeletal muscle mass via gut microbial synthesis of the short‐chain fatty acid butyrate among healthy menopausal womenJournal of Cachexia, Sarcopenia and Muscle, 2021
- The role of prebiotics in cognition, anxiety, and depressionEuropean Neuropsychopharmacology, 2020
- Mendelian RandomizationJAMA, 2017
- Interpreting findings from Mendelian randomization using the MR-Egger methodEuropean Journal of Epidemiology, 2017
- Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median EstimatorGenetic Epidemiology, 2016